Abbott Laboratories secured CE Mark approval in Europe for its Amulet 360 Left Atrial Appendage (LAA) Occluder.
The next-generation device prevents strokes in patients with non-valvular atrial fibrillation who cannot use long-term blood thinners.
Design upgrades include a softer, more conformable lobe to treat diverse patient anatomies. This improvement enhances the seal of the LAA to prevent blood clot formation.
Surgeons in Germany and Denmark completed the first successful procedures with the device. A broader European rollout will begin in the coming weeks.